Exosomes, a category of small lipid bilayer extracellular vesicles that are naturally secreted by many cells (both healthy and diseased), carry cargo made up of proteins, lipids, DNAs, and RNAs; all of which are functional when transferred to their recipient cells. Numerous studies have demonstrated the powerful role that exosomes play in the mediation of cell-to-cell communication to induce a pro-tumoral environment to encourage tumor progression and survival. Recently, considerable interest has developed in regard to the role that exosomes play in immunity; with studies demonstrating the ability of exosomes to either metabolically alter immune players such as dendritic cells, T cells, macrophages, and natural killer cells. In this review, we summarize the recent literature on the function of exosomes in regulating a key process that has long been associated with the progression of cancer—inflammation and immunity.

Keywords: Exosomes, cancer, inflammation, immune molecules, tumorigenesis

INTRODUCTION

Inflammation and Cancer

The inflammatory response is a mechanism that is activated in response to tissue damage or recognition of pathogens, and is facilitated by the action of various cells and soluble mediators of the innate and adaptive immune system (1, 2). In the normal physiological context, once the homeostatic state has been achieved, through the elimination of the foreign pathogen or successful tissue repair, inflammation will be resolved (3). However, if inflammation becomes unregulated and is inadequately resolved it can result in chronic inflammation, which has been linked with an increase in the risk of malignant cell transformation and cancer (2, 4).

The inflammatory and the carcinogenic process share several molecular targets and signaling pathways including apoptosis, proliferation, and angiogenesis. Therefore, sustained exposure to the inflammatory process can contribute to the initiation, promotion, growth, and invasion of tumors by providing bioactive inflammation-related molecules to cells that can infiltrate the tumor microenvironment (1, 2). These molecules include integral players of cancer-related inflammation such as transcription factors NFκB and signal transducer activator of transcription 3 (Stat3), as well as primary inflammatory cytokines such as interleukin (IL)-1β, IL-6, and tumor necrosis factor alpha (TNF-α) (5–8). Accumulation of these inflammatory mediators leads to local and systemic immunosuppression associated with the progression of cancer. Furthermore, several reports have provided accumulating evidence that inflammatory factors are able to down-regulate DNA repair pathways and cell cycle checkpoints, which results in the buildup of random genetic alterations due to the destabilization of the cancer cell genome (9, 10). Additionally, cytokines such as TNF-α and
IL-6 have also been reported to induce the production of free radicals leading to DNA damage and mutations that can further contribute to the initiation of tumors (11, 12).

While inflammation plays a significant role in the promotion of tumor progression, the recruitment of inflammatory cells and up-regulation of anti-inflammatory cytokines by the host is also aimed at suppressing tumor growth. For example, classically activated M1 macrophages exhibit anti-tumor activity and elicit anti-tumor adaptive immunity in the early stages of carcinogenesis (13), by damaging vascular cells and activating coagulation to induce hemorrhagic necrosis (14). However, in established and advanced neoplasia M2-polarized macrophages outweigh M1 macrophages and tumor cells will escape immune attack (13). The balance between the anti-tumor and pro-tumor properties of macrophages is demonstrated to be regulated by NF-κB, thus NF-κB can be targeted to favor the anti-tumor macrophage function (15, 16).

**Cancer-Derived Exosomes**

Exosomes are a category of small lipid bilayer extracellular vesicles that measures approximately 30–100 nm (17–19). The process of exosomes biogenesis (Figure 1) begins with invagination of the plasma membrane to form endosomes. As the endosomes mature, inward budding of the endosome membrane will result in the formation of numerous intraluminal vesicles (ILV) that contain components of the cytosol, including nucleic acids and functional proteins (18, 20–24). The late endosome, now termed multivesicular bodies (MVB), will fuse with the plasma membrane to release the ILVs into the extracellular space, exosomes (25). Exosomes play an integral role in intercellular communication and act as shuttles by transmitting signals and transferring of their contents, thus playing a role in the regulation of physiological and pathological processes of diseases (26–28). The cargo of exosomes is made up of proteins, lipids, DNAs (mtDNA, ssDNA, dsDNA), and RNAs (mRNA, miRNA, long non-coding RNA), which are all functional when transferred into recipient cells (29–32). Exosomes are released from most cell types and can be found in all bodily fluids including urine, plasma, saliva, cerebrospinal fluid, amniotic fluid, and breast milk (33–36).

Extensive reports have illustrated that exosomes derived from tumors are significantly involved in the modulation of the biological activities of their recipient cells via the transfer of their oncogenic content. For example, exosomes play a role in the induction of normal cell transformation. A study has demonstrated that prostate cancer cell-derived exosomes are involved in the clonal expansion of tumors through reprogramming of adipose-derived stem cells via trafficking of oncogenic factors such as H-ras and K-ras transcripts, as well as oncogenic miRNAs miR-125b, miR-130b, and miR-155 (37). Breast cancer cell-derived exosomes have also been shown to promote normal cell transformation. It was determined that exosomes derived from cells and sera of breast cancer patients was able to promote the formation of tumors from non-tumorigenic epithelial cells in a Dicer-dependent manner (38). Other biological activities affected by tumor-derived exosomes include cell proliferation; as observed in colon cancer cells whereby a transfer of exosomes from colon tumor cells was able to induce a rise in cell proliferation and chemoresistance in acceptor cells both in vitro and in vivo (39). Up-regulation of angiogenesis has also been detected to be influenced by tumor-derived exosomes. One study demonstrated that leukemia cells-derived exosomes was able to transport miRNAs (miR-92a) to endothelial cells to modulate endothelial migration and tube formation (40). The metastatic ability of cells can also be modulated by tumor derived-exosomes. Exosomes isolated from melanoma cells of stage V patients is able to stimulate the formation of a metastatic niche by encouraging bone marrow-derived cells toward a pro-metastatic phenotype via up-regulation of the MET oncoprotein (41). Furthermore, there is potential for the development of exosomes as diagnostics biomarkers as they contain all the bioactive molecules of the cells they are derived from (42–46).

Recently considerable interest has developed in regard to the role that exosomes play in the immune response, with studies demonstrating the ability of exosomes to either promote or inhibit immune responses. For example, exosomes derived from thrombin-activated platelets are able to stimulate the proliferation, survival, and chemotaxis of hematopoietic cells (47) as well as activate monocytes to release pro-inflammatory cytokines and induce the activation of B cells (48). Furthermore, exosomes released by antigen presenting cells such as B-lymphocytes and dendritic cells contain MHC class I molecules that are able to potentially mediate antigen-specific T cell cross-priming (49–53). Natural killer (NK) cells-derived exosomes have also been shown to mediate anti-tumor activities via its cellular content perforin and granzyme B, which has cytotoxic activity against various tumor cell lines (54). It has also been reported that peptides expressed in exosomes derived from mast cells can be presented to dendritic cells to stimulate specific immune responses (55). Various immune suppressive roles of exosomes include the promotion of apoptosis in activated T cells via expression of death ligands FasL (56) and TRAIL (57); impairment of dendritic cell differentiation from monocytes (58); as well as the suppression of NK cells mediated cytotoxic responses (59).

**PRO-INFLAMMATORY EFFECTS OF EXOSOMES**

**Monocytes**

Monocytes are a subset of mononuclear leukocytes, or circulating white blood cells, which differentiates into macrophages and dendritic cells following stimulation by cytokines and other molecules (60, 61). Monocytes play a significant role in both innate and adaptive immunity (62) through the production of various effector molecules such as inflammatory cytokines, myeloperoxidase, and superoxide, to contribute toward and initiate local and systemic inflammation (63, 64). During chronic inflammation, cytokines have been reported to promote the creation of ideal growth conditions within the tumor microenvironment as well as to promote the progression of tumor growth (65–67). Tumor cells and its
associated microenvironment can produce molecules that alter the recruitment, migration, differentiation, and functional properties of monocytes (68).

Exosomes produced and released by tumor cells contain various biomolecules that can be transmitted to recipient cells, including monocytes, to regulate their behavior. In a study conducted in 2013 by Bretz et al. it was demonstrated that exosomes obtained from malignant ascites of ovarian cancer patients were able to modulate the biological functions of monocytic cells (69). Results indicated that tumor-derived exosomes were transferred into the THP-1 human monocytic cells and significantly induced the production and secretion of various pro-inflammatory cytokines including interleukin (IL)-6, IL-1β, and IL-8, and tumor necrosis factor (TNF)-α, via TLR2 and TLR4 binding on the cell surface of monocytes, which subsequently activated nuclear factor κB (NFκB) and signal transducer and activator of transcription 3 (STAT3) (69). NF-κB is a significant regulator of inflammation, and constitutive activation of NFκB is often observed in cancer cells and is associated with an aggressive phenotype, which includes tissue invasion and metastasis as well as resistance to growth inhibition (70). NF-κB is activated downstream of the TLR-MyD88 pathway and inflammatory cytokines TNF-α and IL-1β (9). Furthermore it has recently been shown that STAT3 is required for the activation of NFκB and interaction between these two transcription factors is essential for the regulation of communication between inflammatory and cancer cells. Together, NFκB and STAT3 have the capability to regulate apoptosis, angiogenesis, and tumor invasion thus enabling resistance toward immune surveillance (1, 71).

The role of tumor-derived exosomes in the cross-talk with monocytes was also evaluated in a separate study focused on chronic lymphocytic leukemia (CLL). CLL-derived exosomes was found to play a role in the skewing of monocytes and macrophages toward a pro-tumorigenic phenotype with the release of tumor-supportive cytokines as well as the expression of immunosuppressive molecules such as programed cell death 1 ligand (PD-L1). Furthermore, the authors discovered that non-coding Y RNA hY4 transcript was enriched in CLL-derived exosomes and acts as a ligand to facilitate the significant increase in secretion of CCL2, CCL3, CCL4, CXCL10, and IL-6 via TLR7 signaling (72).

**Macrophages**

Macrophages immune cells that have important roles in antigen presentation, phagocytosis, and immunomodulation (73, 74) and their functional phenotypes are extremely versatile and dependent upon the tissue type and signals presented within it’s microenvironment, thus allowing macrophages to play multiple roles in the inflammatory process (74–76). Activation of M1-phenotype macrophages leads to immunostimulation, with an increase in production of pro-inflammatory cytokines and chemokines leading to the effective elimination of pathogens and infection (77, 78), while the M2 macrophages are anti-inflammatory and promote progression of tumors, stimulate angiogenesis and wound healing (78, 79). Various studies have reported the mechanisms by which intercellular communication between cancer cells and tumor-associated macrophages, via exosomes, can regulate the function and phenotype of these immune cells.

Breast (80) and gastric (81) tumor-derived exosomes can induce a M1 pro-inflammatory response in macrophages through the activation of NFκB, which in turn stimulates production of inflammatory cytokines including GCSF, IL-6, IL-8, IL-1β, CCL2, and TNF-α. Chow et al. in 2014 further revealed that the activation of NFκB is mediated by the interaction...
between breast cancer-derived exosomes and macrophages, and it is largely influenced by the presence of TLR2 and palmitoylated protein ligands on the surface of macrophages and tumor-derived exosomes, respectively (80). In another study, NfκB in macrophages was activated through binding of miR-21 and miR-29a, secreted by tumor-derived exosomes, to murine TLR7 and human TLR8, to trigger a TLR-mediated protumorigenic inflammatory response to promote tumor growth and metastasis (82).

Annexin A2, which is highly expressed in breast-cancer-derived exosomes, has also been reported to play a role in macrophage-mediated inflammatory response (83). Annexin A2 mediates M1 macrophage activation of p38MAPK, NfκB, and STAT3 pathways by increasing the secretion of IL-6 and TNF-α. Furthermore, priming of animals with breast cancer-derived exosomes containing high annexin A2, led to an increased level of VEGFR1 in lung and brain sections, with a concordant increase in MMP9 in tissues. Up-regulation of VEGFR1 and MMP9 expression by tumor-derived exosomes was linked with breast cancer metastasis and extracellular proteolysis and angiogenesis, respectively (83).

**Dendritic Cells**

Dendritic cells are professional antigen-presenting cells (APCs) that functions to recognize, process, and present antigens to T cells of the immune system via major histocompatibility complex (MHC) molecules, along with co-stimulatory molecules and cytokines to initiate the immune system (84). Tumor-derived exosomes have been reported to be potent immune suppressors via inhibition of dendritic cell differentiation. Results from a study conducted by Yu et al. in 2007 demonstrated that administration of exosomes caused an accumulation of undifferentiated myeloid precursor cells in the spleen of mice, and in vitro introduction of exosomes to myeloid precursor cells resulted in the blockage of differentiation. This inhibition of dendritic cell differentiation is mediated through the induction of IL-6 by tumor-derived exosomes (85). In another study, tumor-derived exosomes was able to inhibit the differentiation of human monocyte precursors into dendritic cells in melanoma and colorectal cancers. Additionally, these monocytes gained the ability to secrete TGFB further inhibiting the proliferation of T lymphocytes (86). Recently a study has determined that tumor-derived exosomes (TEX)‐activated dendritic cells (Ta‐TEXs) are able to increase the production of inflammatory mediators of dendritic cells, which include IL-6 and prostaglandin E1 (PGE1). The binding of a natural ligand, Hsp105, found on the surface membrane of tumor-derived exosomes to TLR2 and TLR4, stimulates the secretion of IL-6 and PGE1. This in turn leads to an increase in tumor cell invasion and metastasis via phosphorylation of STAT3, which in turn promotes the transcription of matrix metalloproteinase 9 (MMP9) by binding to the MMP9 promoter (87). Furthermore, pancreatic cancer-derived exosomes have been reported to down-regulate the expression of TLR4 expression in dendritic cells, via the transfer of miR-203. This led to a subsequent decrease in expression of TNF-α and IL-12 (88).

**Myeloid Derived Suppressor Cells (MDSC)**

Myeloid derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells comprised of precursors of dendritic cells, macrophages, and granulocytes. The accumulation of MDSCs in tumor-bearing mice (89) and humans (90, 91) have been widely reported, and mounting evidence has indicated that the tumor microenvironment produces various factors that inhibit the maturation and differentiation of these immunoregulatory cells (92–94). The accumulation of MDSCs has been shown to play a role in the promotion of tumor progression, by suppressing antigen processing and presentation as well as T cell activation, which consequently inhibits immune surveillance and anti-tumor immunity (95–97).

Tumor-derived exosomes have the ability to induce the accumulation of MDSCs in tumors. Yu et al. reported that tumor-derived exosomes can be taken up by bone marrow precursor cells and induce a switch in the differentiation pathway of these myeloid cells to the MDSC pathway (85). The tumor microenvironment then increases the recruitment of immune suppression molecules PGE2 and TGF-β, into the exosomes, which then facilitates tumor growth through the induction of pro-inflammatory cytokine Cx2. These tumor exosomes were also found to release pro-inflammatory cytokines IL-6 and tumor growth factor VEGF further enhancing its role in tumor growth (98). Exosome Hsp70 (99) and Hsp72 (100) have both been reported to expand and induce the activation of MDSCs. When treated with exosomal Hsp70 and Hsp72, MDSCs was found to significantly increase the production of pro-inflammatory cytokines including IL-6, TNF-α, VEGF, and CCL2, leading to an increase in tumor growth and metastasis (100). In accordance with these changes in phenotype, exosomal Hsp70 was also found to trigger phosphorylation of STAT3 in a TLR2-MyD88-dependent manner (101).

MyD88 is a key cytoplasmic adaptor protein required for the integration and transduction of signals generated by the TLR family (101). Recent reports have determined that MyD88 plays a critical role in the inhibition of myeloid cell differentiation into dendritic cells. Results from a study conducted by Liu et al., found that melanoma exosomes have no inhibitory effect on the differentiation of bone marrow (BM) precursor cells isolated from MyD88 knockout mice, whereas an inhibitory effect was observed with BM precursor cells isolated from wild-type mice. Furthermore, significant reduction was observed in the percentage of dendritic cells in wild-type mice exposed to melanoma exosomes, while no significant effects was observed in MyD88 knockout mice (101). This indicates that MyD88 plays a crucial role to the induction of MDSCs.

Furthermore, exosomes derived from MDSCs have been reported to promote tumor progression by facilitating the polarization of M1 macrophages with a tumorcidal phenotype, to a tumor-promoting M2 macrophage, via inhibition of macrophage production of IL-2 production (102).

**Others**

As previously described, communication between cancer cells and their microenvironment can be mediated via exosomes.
through the transfer of their cargo which includes proteins, DNAs, messenger RNAs and microRNAs (103–105). For example, exosomes originating from arsenite-transformed hepatic epithelial cells, L-02 cells, can induce a pro-inflammatory reaction in normal liver cells by transferring exosomal miR-155 (106). Briefly, in response to arsenite exposure, NfkB will be activated to promote the overexpression of miR-155, which in turn will be transferred to normal liver cells via exosomes to influence the production of IL-6 and IL-8 to evoke a pro-inflammatory response via STAT3 (106–108). Exosomes have also been reported to secrete proteins to initiate an inflammatory response. A study has described the release of an enzyme known to be essential for protein synthesis, lysyl-tRNA synthetase (KRS), from exosomes derived from colorectal carcinoma cells (109). Caspase 8 was found to facilitate the secretion of KRS from exosomes, which in turn induced the release of cytokines and factors that are known markers for M1 and M2 macrophages, including TNF-α, C-X-C motif chemokine ligand 10 (CRG2), IL-6 and MMP9 (109). Heat shock protein, crystallin alpha B (CRYAB) has also been described to be released from glioblastoma multiforme (GBM) derived-exosomes in response to exposure to pro-inflammatory cytokines IL-1β and TNF-α, to exert an anti-apoptotic activity (110). Furthermore, results indicated that following an increase in cytokine levels in GBM cells, due to either radiation or disease, significant changes occur in the GBM derived-exosomal proteome which may promote progression of inflammation, tumor invasiveness, angiogenesis, and tumor progression (110).

ANTI-INFLAMMATORY EFFECTS OF EXOSOMES

Tumor inflammation plays a crucial part in the advancement of initiation, promotion, and progression of tumourigenesis through the development of a pro-tumorigenic microenvironment. This can be achieved by exosomes through the suppression of the immune system and prevention of uncontrolled inflammation. For example, exosomes can induce immunosuppression through the initiation of apoptosis in immune cells (111). In Epstein-Barr virus (EBV)-infected nasopharyngeal cells, released exosomes contain high concentrations of galectin-9 protein, which is able to induce apoptosis in mature Th1 lymphocytes (112, 113). Tumor-derived exosomes have also exhibited the ability to trigger Fas-dependent apoptosis of activated CD8+ T cells in both colorectal cancer as well as melanoma cells, thus contributing to tumor escape from the immune system (56, 114, 115).

Natural Killer Cells

Natural killer (NK) cells are innate lymphoid cells that are involved in the protection of the host against infection and cancerous cells, as well as the regulation of homeostasis via destruction of activated immune cells (116, 117). Tumor-derived exosomes have been reported to suppress the activity of NK cells as a means to promote immune escape of cancer cells. These tumor-derived exosomes are able to arrest NK cell development through the release of the immunosuppressive cytokine transforming growth factor-β (TGF-β) (118). Furthermore, in a study using syngeneic BALB/c and nude mice, exosomes derived from TS/A or 4T.1 murine mammary tumor cells was able to induce tumor growth by inhibiting IL-2 mediated activation of NK cells (119). NK cell proliferation was also reported to be inhibited by exosomes produced by human breast and melanoma cell lines (119). Tumor derived exosomes have also been shown to induce Smad phosphorylation, impair cell cytotoxicity, and decrease NKG2D receptor expression, which will result in the loss of tumor cell surface markers, that would in normal situations stimulate immune response (120–122). Furthermore, exosomes are able to act as decoys by secreting NKG2D ligands, which will down-regulate NKG2D receptor-mediated cytotoxicity of NK cells (123).

Regulatory T Cells (Treg)

Regulatory T cells (Tregs) are a dedicated subset of a larger, heterogeneous population of CD4+ T cells (124, 125), that has an important function in immune homeostasis, as well as a role in the regulation of various inflammatory process including autoimmunity, tissue injury, and transplant rejection (126–128). In cancer, Tregs have been found to be accumulated in the tumor microenvironment and plays a significant role in maintenance of immune tolerance via the suppression of various immune cells such as T lymphocytes (129), B lymphocytes (130), NK cells (131), dendritic cells (132), and macrophages (133). Patients with high density of Tregs in the tumor stroma have also been shown to have a worse prognosis in comparison to those with low density of Tregs (134).

Tumor derived exosomes can initiate immunosuppression through the indirect expansion and activation of Treg. This will lead to an up-regulation of Treg suppression function and enhancing Treg resistance to apoptosis (135, 136). Szajnik et al. reported that the expression of CD24+CD25+FOXP3+ Treg cells is significantly increased in the peripheral blood of myeloma patients in comparison to non-cancerous donors, and the serum of these patients contained high concentrations of tumor-derived exosomes. They further determined that tumor-derived exosomes was able to induce Treg expansion through mechanisms involving phosphorylation of relevant transcription factors IL-10 and TGF-β1 (136).

Macrophages

In hepatocellular carcinoma, exosomes are able to indirectly down-regulate expression of the pro-inflammatory cytokine IL-6 as a means of suppressing the immune system. A study has demonstrated that TLR4, a fundamental signaling pathway that mediates inflammation (137, 138), was found to regulate uncontrolled inflammation through the release of exosomes via the MyD88 dependent pathway. Exosomes in turn transferred miR-let-7b to macrophages to inhibit the expression of pro-inflammatory IL-6, thus weakening tumor inflammation (139).

In another study, macrophages were found to be affected by the overexpression of miR-940 released by exosomes
| Immune cell | Exosomes derived from | Cargo released | Role in cancer development | References |
|-------------|----------------------|----------------|---------------------------|------------|
| **PRO-INFLAMMATORY EFFECTS OF EXOSOMES** | | | | |
| Monocytes | Ovarian cancer | IL-6, IL-1β, TNF-α | Increased invasion and metastasis | (69) |
| | Chronic lymphocytic leukemia | PD-L1, Y RNA hY4→CCL2, CCL3, CCL4, CXCL10, IL-6 | Skew monocytes and macrophages toward pro-tumorigenic phenotype | (72) |
| Macrophages | Breast cancer | GCSF, IL-6, IL-8, IL-1β, CCL2, TNF-α | M1 macrophage activation | (80) |
| | Gastric cancer | GCSF, IL-6, IL-8, IL-1β, CCL2, TNF-α | M1 macrophage activation | (81) |
| | Lung cancer | miR-21, miR-29a | Trigger TLR-mediated pro-metastatic inflammatory response | (82) |
| | Breast cancer | Annexin A2, IL-6, TNF-α | M1 macrophage activation | (83) |
| Dendritic cells | Breast cancer | IL-6 | Inhibition of dendritic cell differentiation | (85) |
| | Melanoma and colorectal cancer | IL-6, PGE1 | Activates dendritic cells | (87) |
| | Pancreatic cancer | miR-203 | Increase tumor cell invasion & metastasis | (88) |
| | MDSCs | Murine mammary adenocarcinoma | PGE2, TGF-β, Cox2, IL-6, VEGF | Expansion of myeloid-derived suppressor cells | (98) |
| | Renal cell carcinoma | Hsp70 | Increase production of pro-inflammatory cytokines | (99) |
| | Murine colon carcinoma | Hsp72 | Promote MDSC suppressive functions | (100) |
| | Murine mammary carcinoma | – | Polarization of M1 macrophages to M2 macrophage | (101) |
| Others | Arsenite hepatic epithelial cells | miR-155 | Increase IL-6 and IL-8 to induce pro-inflammatory response | (102) |
| | Colorectal carcinoma | Lysyl-tRNA synthetase (KRS) | Induce release TNF-α, CRG2, IL-6, and MMP9 | (103) |
| | Glioblastoma multiforme | CRYAB | Induce anti-apoptosis, invasion, angiogenesis and tumor progression | (110) |

| ANTI-INFLAMMATORY EFFECTS OF EXOSOMES | | | | |
| Natural killer cells | Acute myeloid leukemia | TGF-β | Suppress activity of NK cells | (118) |
| Natural killer cells | Murine mammary tumor cells | – | Inhibiting IL-2 mediated activation of NK cells | (119) |
| Breast cancer and mesothelioma | Leukemia | NKG2D ligands | Down-regulate NKG2D receptor-mediated cytotoxicity of NK cells | (120–122) |
| Treg cells | SCCHN and oral cavity squamous cell carcinoma | – | Expansion and activation of regulatory T cells | (123) |
| | Macrophages | Hepatocellular carcinoma | miR-let-7b | Inhibit expression of IL-6 in macrophages | (124) |
| | | Hypoxic ovarian cancer | miR-940 | Weaken tumor inflammation | (125) |
| | | Epithelial ovarian cancer | miR-222-3p | Increase polarization of M2 macrophages | (126) |
| | | Glioblastoma-derived stem cells | PD-L1 | Increase polarization of M2 macrophages | (127) |

(Continued)
derived from hypoxic ovarian cancer cells, inducing an anti-inflammatory M2 polarization of macrophages to promote epithelial ovarian cancer (EOC) cell proliferation and migration (140). Another miRNA, miR-222-3p, enriched in EOC-derived exosomes, has also been revealed to increase polarization of M2 macrophages to promote angiogenesis and lymphangiogenesis in the tumor microenvironment to further encourage progression of EOC (141). Results indicated that miR-222-3p directly targets SOCS3 (suppressor of cytokine signaling 3), a negative regulator of the JAK/STAT pathway (142), which has been described to control the polarization of M1 and M2 macrophages (143–145). Suppression of SOCS3 expression was found to correlate with an increased expression of STAT3 activation (146).

A shift to M2 polarization can also be seen in macrophages exposed to exosomes released from colon cancer cells harboring gain-of-function mutant p53. These exosomes contain significantly high levels of miR-1246 which when transferred to neighboring macrophages stimulate heightened secretion of anti-inflammatory cytokines and epithelial-mesenchymal (EMT) promoting factors, thus contributing to tumorigenesis and poor prognosis (147). Another method through which exosomes mediate the polarization of M2 macrophages is by traversing the monocyte cytoplasm to induce a change in morphology and reorganization of the actin cytoskeleton. These exosomes secreted from glioblastoma-derived stem cells (GSCs) stimulate an increase of programmed death-ligand 1 (PD-L1) in monocytes, via association with STAT3, to mediate this suppressive switch (146).

In turn macrophages are also able to induce the release of exosomes to shuttle miRNAs into adjacent cells within the microenvironment. In response to activation by anti-inflammatory molecule IL-4, macrophages from breast cancer tumors has demonstrated the ability to release exosomes containing miR-233 which plays a role in tumor growth, invasion, and metastasis via direct targeting of myocyte enhancer factor (Mef2c) (148).

**FUTURE PERSPECTIVE ON EXOSOMES IN IMMUNOTHERAPY**

As evidenced by the numerous studies, exosomes have the ability to suppress or activate the immune system through regulation of various immune cells. Due to key features of exosomes, such as their structure, composition, and their natural ability to transport and transfer their cargo among cells, exploitation of exosomes has been acknowledged as a feasible means of immunotherapy and treatment of cancer.

Loading of immunotherapy elements such as tumor associated antigens and adjuvants into exosomes have been reported to induce strong antigen-specific immunostimulatory effects (149). For example, in one study by Morishita et al. a murine melanoma B16-BL6 tumor cell-derived exosome was engineered to carry endogenous tumor antigen and streptavidin-lactadherin, which facilitated the delivery of biotinylated CpG DNA. Delivery of these exosomes in immunized B16-BL6 tumor-bearing mice induced an in vivo anti-tumor effect (150). In another study by Mahmoodzadeh et al., MDA MB-231 cancer cell exosomes were loaded with staphylococcal enterotoxin B, which functions to activate T cells through the binding of MHCII. Estrogen receptor-negative (ER-) breast cancer cells treated with these exosomes were then observed to undergo significant apoptosis (151). Furthermore, studies have shown that loading of exosomes with miRNAs also has the potential to induce immune responses in their recipient cells. Momem-Heravi et al. demonstrated that B-cell-derived exosomes loaded with miR-155 was able to target macrophages in vitro and in vivo and induce the activation and differentiation of macrophages to an inflammatory M1-phenotype (152). Currently there are a number of methods to load exosomes with the desired cargo, which includes electroporation, sonication, direct transfection, and simple incubation (153). However, further understanding of the limitations and advantages of these techniques must be

---

**TABLE 1 | Continued**

| Immune cell type | Exosomes derived from | Cargo released | Role in cancer development | References |
|------------------|-----------------------|----------------|---------------------------|------------|
| **ANTI-INFLAMMATORY EFFECTS OF EXOSOMES** |
| Colon cancer     | miR-1246              | –              | Increase polarization of M2 macrophages | (147) |
|                  |                       |                | Increase epithelial-mesenchymal (EMT) promoting factors | |
|                  |                       |                | Contribute to tumourigenesis and poor prognosis | |
| Breast cancer    | miR-233               | Galectin-9     | Tumor growth, invasion, and metastasis | (148) |
| EBV-infected nasopharyngeal carcinoma | Galectin-9 | – | Induce apoptosis of mature Th1 lymphocytes | (111) |
| Others           | Squamous cell carcinoma of the head and neck (SCCHN) and melanoma | – | Fas-dependent apoptosis of activated CD8+ T cells | (114) |
| Colorectal       | –                     |                | Tumor escape from immune system | |

*Note: The table continues with additional data on other immune cells and their roles.*
FIGURE 2 | Scheme depicting the pro-inflammatory effects of tumor-derived exosomes on immune molecules.

FIGURE 3 | Scheme depicting the anti-inflammatory effects of tumor-derived exosomes on immune molecules.
studied to improve the potential of exosomes as a mode of immunotherapy.

Dendritic-cell (154)-derived exosome therapy is another is another means of inducing immune response for cancer treatment. In this therapy, dendritic cells with cancer peptides are stimulated to induce the production of DC-derived exosomes that carry the desired antigens. These DC-derived exosomes are then isolated, purified, and used to induce an immune response either through presenting of specific antigens to T cells to directly activate them, or through indirect activation through the presentation of antigen-MHC complex transfer to other dendritic cells (52, 53, 155). The immune stimulatory effects of DC-derived exosomes have shown promising, but modest, results in two phase I human clinical trials in melanoma and non-small-cell lung cancer (156, 157). Subsequently, a phase II clinical trial in advanced non-small-cell lung cancer patients pre-treated with chemotherapy has shown limited efficacy of DC-derived exosomes to stimulate NK cell activation and improve the progression-free survival of patients (158).

The possibility of using exosomes as a means for cancer immunotherapy is still developing and there remain many challenges to overcome. Further knowledge must be obtained regarding the many roles that exosomes play in cancer and immunomodulation as well as the logistics for the development of exosomes as an immunotherapy. These include further research regarding techniques for effective isolation of exosomes, the possibility of off-target effects due to the transfer of unknown materials in exosomes, as well as the amount, type, and biological functions of the biomolecules to be loaded into the exosomes (159, 160).

**CONCLUSION**

Chronic inflammation has long been accepted to contribute to the development and pathogenesis of various cancers. Recently, many studies have explored the interaction of exosomes with the inflammatory system in promoting a pro-tumor microenvironment. As summarized in **Table 1**, **Figures 2, 3**, exosomes are able to induce pro-inflammatory and anti-inflammatory effects through the release of their cargo, which in turn modulates various cancer mechanisms including angiogenesis, metastasis, invasion, and apoptosis. Together these studies have demonstrated the importance of understanding the intricate crosstalk that exists between tumor-derived exosomes and immune molecules, as a means to acquire further understanding of the development of cancers especially in those suffering inflammatory disorders.

**AUTHOR CONTRIBUTIONS**

NO drafted the manuscript. NA conceived the idea. NA and RJ provided critical feedback.

**FUNDING**

This manuscript was funded by the GGPM (Young Investigator Grant) Award by Universiti Kebangsaan Malaysia with the award number GGPM-2017-096.

**REFERENCES**

1. Fernandes JV, Cobucci RN, Jatoba CA, Fernandes TA, de Azevedo JW, de Araujo JM. The role of the mediators of inflammation in cancer development. Pathol. Oncol. Res. (2015) 21:527–34. doi: 10.1007/s12253-015-9913-x

2. Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res. (2014) 2014:19. doi: 10.1155/2014/149185

3. Norling LV, Serhan CN. Profiling in resolving inflammatory exudates identifies novel anti-inflammatory and pro-resolving mediators and signals for termination. J Intern Med. (2010) 268:15–24. doi:10.1111/j.1365-2769.2010.02235.x

4. Bermejo-Martín JF, Martín-Loeches I, Bosingier S. Inflammation and infection in critical care medicine. Mediat Inflamm. (2014) 2014:456256. doi: 10.1155/2014/456256

5. Karin M. Nuclear factor-kB in cancer development and progression. Nature. (2006) 441:431–6. doi: 10.1038/nature04870

6. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol. (2007) 7:41–51. doi: 10.1038/nri1995

7. Voronov E, Shouval DS, Krelin Y, Cagnano E, Benharroch D, Iwakura Y, et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA. (2003) 100:2645–50. doi: 10.1073/pnas.0437939100

8. Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K. IL-23 promotes tumour incidence and growth. Nature. (2006) 442:461–5. doi: 10.1038/nature04808

9. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. (2009) 30:1073–81. doi: 10.1093/carcin/bgq127

10. Nowell PC. The clonal evolution of tumor cell populations. Science. (1976) 194:23–28. doi: 10.1126/science.959840

11. Yang D, Elner SG, Bian ZM, Till GO, Petty HR, Elner VM. Pro-inflammatory cytokines increase reactive oxygen species through mitochondria and NADPH oxidase in cultured RPE cells. Exp Eye Res. (2007) 85:462–72. doi:10.1016/j.exer.2007.06.013

12. da Silva Krause M, Bittencourt A, Homem de Bittencourt PI Jr, McClennaghan NH, Flatt PR, Murphy C, et al. Physiological concentrations of interleukin-6 directly promote insulin secretion, signal transduction, nitric oxide release, and redox status in a clonal pancreatic beta-cell line and mouse islets. J Endocrinol. (2012) 214:301–11. doi: 10.1530/JOE-12-0223

13. Allavena P, Sica A, Garlanda C, Mantovani A. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol Rev. (2008) 222:155–61. doi: 10.1111/j.1600-065X.2008.00607.x

14. Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L. The origin and function of tumor-associated macrophages. Immunol Today. (1992) 13:265–70. doi: 10.1016/0167-5699(92)90008-U

15. Saccani A, Schioppa T, Porta C, Biswas SK, Nebuloni M, Vago L, et al. p50 nuclear factor-kB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res. (2006) 66:11432–40. doi: 10.1158/0008-5472.CAN-06-1867

16. Hagemann T, Lawrence T, McNeish I, Charles KA, Bulke H, Thompson RG, et al. “Re-educating” tumor-associated macrophages by targeting NF-kB. J Exp Med. (2008) 205:1261–8. doi: 10.1084/jem.20080108
17. Keller S, Sanderson MP, Stoeck A, Alvegott P. Exosomes: from biogenesis and secretion to biological function. *Immunol. Lett.* (2006) 107:102–8. doi: 10.1016/j.iol.2006.09.005

18. Colombo M, Raposo G, Thery C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. *Ann Rev Cell Dev Biol.* (2014) 30:255–73. doi: 10.1146/annurev-cellbio-101512-123236

19. Thery C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. *Nat Rev Immunol.* (2002) 2:569–79. doi: 10.1038/nri5855

20. Coccucci E, Meldolesi J. Exosomes and exosome: shedding the confusion between extracellular vesicles. *Trends Cell Biol.* (2015) 25:364–72. doi: 10.1016/j.tcb.2015.01.004

21. Trajkovic K, Hsu C, Chiantia S, Rajendran L, Wenzel D, Wieland F, et al. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. *Science.* (2008) 319:1244–7. doi: 10.1126/science.1153124

22. Silva M, Melo SA. Non-coding RNAs in exosomes: new players in cancer biology. *Curr Genom.* (2015) 16:295–303. doi: 10.2174/1389202916666150707154719

23. Crescitielli R, Lasser C, Szabo TG, Kittel A, Eldh M, Dianzani I, et al. Distinct RNA profiles in subpopulations of extracellular vesicles: apoptotic bodies, microvesicles and exosomes. *J Extracell Vesicles.* (2013) 2:20677. doi: 10.3402/jev.v2i0.20677

24. Kalra H, Simpson RJ, Ji H, Aikawa E, Altevogt P, Askenase P, et al. Vesiclepedia: a compendium for extracellular vesicles with bodies, microvesicles and exosomes. *Distinct RNA profiles in subpopulations of extracellular vesicles: apoptotic bodies, microvesicles and exosomes.* *J Extracell Vesicles.* doi: 10.2174/1389202916666150707154719

25. Record M, Subra C, Silvente-Poirot S, Poirot M. Exosomes as intercellular signalosomes and pharmacological effectors. *Biochim Pharmacol.* (2011) 81:1171–82. doi: 10.1016/j.bcp.2011.02.011

26. Zhang X, Yuan X, Shi H, Wu L, Qian H, Xu W. Exosomes in cancer: small particle, big player. *Cancer Cell.* (2014) 26:707–21. doi: 10.1016/j.ccell.2014.09.005

27. Gallo A, Tandon M, Alevizos I, Illei GG. The majority of microRNAs detectable in serum and saliva is concentrated in exosomes. *PloS ONE.* (2012) 7:e30679. doi: 10.1371/journal.pone.0030679

28. Kucharzewska P, Belting M. Emerging roles of extracellular vesicles in the interactions of exosomes and other extracellular vesicles. *Ann Rev Cell Dev Immunol.* (2014) 30:255–73. doi: 10.1146/annurev-cellbio-101512-123236

29. Kahlert C, Melo SA, Protopopov A, Tang J, Seth S, Koch M, et al. Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer. *J Biol Chem.* (2014) 289:3689–75. doi: 10.1074/jbc.C113.532267

30. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nat Cell Biol.* (2007) 9:545–9. doi: 10.1038/ncl.20061450

31. Lasser C, Alikhani VS, Ekstrom K, Eldh M, Paredes PT, Bossios A, et al. Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein hsc73. *J Immunol.* (2003) 170:3037–45. doi: 10.4049/jimmunol.170.6.3037
56. Andreola G, Rivoltini L, Castelli C, Huber V, Perego P, Deho P, et al. Induction of lymphocyte apoptosis by tumor cell secretion of Fasl-bearing microvesicles. J Exp Med. (2002) 195:1530–16. doi: 10.1084/jem.20011624

57. Taylor DD, Gercel-Taylor C. Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects. Br J Cancer. (2005) 92:303–11. doi: 10.1038/sj.bjc.6602316

58. Clayton A, Mason M. Exosomes in tumour immunity. Curr Oncol. (2009) 16:46–49. doi: 10.3734/cvo.16.3.367

59. Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol. (2010) 22:231–7. doi: 10.1016/j.coi.2010.01.009

60. Biwas SK, Gangi L, Paul S, Schioppa T, Saccani A, Sironi M, et al. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NFKB and enhanced IRF-3/STAT1 activation). Blood. (2006) 107:2112–22. doi: 10.1182/blood-2005-01-0428

61. Wu L, Zhang X, Zhang B, Shi H, Yuan X, Sun Y, et al. Exosomes derived from gastric cancer cells activate NFKB pathway in macrophages to promote cancer progression. Tumour Biol. (2016) 37:12169–80. doi: 10.1007/s13277-016-5071-5

62. Fabbri M, Paone A, Calore F, Galli R, Gaudio E, Santanam R, et al. MiCroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci USA. (2012) 109:E2110–6. doi: 10.1073/pnas.1209441109

63. Matsuda M, Ouchi N, Tanaka K, Kishimoto T. Adipocytokines as key regulators of inflammation and immune responses. Nat Rev Endocrinol. (2015) 11:596–608. doi: 10.1038/nrendo.2015.67

64. Harker LA, Altman J, Determan DD, Greaves M. Cell types and their functions in the tumor microenvironment. Nat Rev Cancer. (2016) 16:209–24. doi: 10.1038/nrc.2016.43

65. Kaestel T, Liebisch G, Vukicevic M, Koppmann R, Barysheva N, Hippe S, et al. Inflammatory cytokines promote regeneration of hematopoietic progenitor cells. Blood. (2008) 111:3175–82. doi: 10.1182/blood-2007-06-112121

66. Mantovani A, Sica A. Macrophages, innate immunity and cancer: the role of reactive oxygen species. Nat Rev Immunol. (2010) 10:536–47. doi: 10.1038/nri2826

67. Kaminski N, Kim S, Schadt EE, Glass RT, Israeli J, Blattner WA, et al. Immune and inflammatory gene expression profiles in human cancers. Cancer Res. (2005) 65:9181–91. doi: 10.1158/0008-5472.CAN-05-3504

68. Robinton DA, Linsley PS, Pugh CW, Greten FR, Greten TF, Aderem A, et al. Inflammatory and immune genes in breast cancer. Cancer Cell. (2006) 10:277–89. doi: 10.1016/j.ccr.2006.07.009

69. Mantovani A, Sozzani S, Locati C, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. (2002) 23:549–55. doi: 10.1016/S1471-4906(02)02302-5

70. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. (2008) 8:958–69. doi: 10.1038/nri2448

71. Mantovani A, Sica A. Macrophages, innate immunity and cancer: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol. (2010) 40:2969–75. doi: 10.1002/eji.201040895

72. Whiteside TL. Exosomes and tumor-mediated immune suppression. J Clin Invest. (2016) 126:1216–23. doi: 10.1172/JCI81136

73. Musolin C, Allegra A, Piogga G, Gangemi S. Immune myeloid-derived suppressor cells: a bridge between inflammation and cancer (Review). Oncol Rep. (2017) 37:671–83. doi: 10.3892/or.2016.5291

74. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol. (2009) 182:4499–506. doi: 10.4049/jimmunol.0802740
101. Liu Y, Xiang X, Zhuang X, Zhang S, Liu C, Cheng Z, et al. Abels ER. Introduction to extracellular vesicles: biogenesis, RNA cargo.

102. Burke M, Choksawangkarn W, Edwards N, Ostrand-Rosenberg S, Fenselau C. Exosomes from myeloid derived suppressor cells carry biologically active proteins. J Proteome Res. (2014) 13:836–43. doi: 10.1021/pr400879c

103. Jablonski KA, Gaudet AD, Amici SA, Popovich PG, Guerau-de-Arellano JP, et al. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest. (2010) 120:457–71. doi: 10.1172/JCI40483

104. Choi DS, Kim DK, Kim YK, Gho YS. Proteomics, transcriptomics and double-stranded DNA in exosomes: a novel biomarker in cancer detection. Cell Mol Neurobiol. (2014) 34:2621–33. doi: 10.1007/s10571-016-0366-z

105. Thakur BK, Zhang H, Becker A, Matei I, Huang Y, Costa-Silva B, et al. Hsc70 binds to exosomal membrane and protects membrane-bound proteins. Biophys Res Commun. (2018) 511:1282–95. doi: 10.1016/j.bbrc.2018.08.001

106. Chen C, Luo F, Liu X, Lu L, Xu H, Yang Q, et al. NF-kB-regulated exosomal immunosuppressive activity is shed by tumor cells in exosomes. Cancer Lett. (2009) 286:1436–44. doi: 10.1016/j.canlet.2009.08.001

107. Jablonski KA, Gaudet AD, Amici SA, Popovich PG, Guerau-de-Arellano JP, et al. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest. (2010) 120:457–71. doi: 10.1172/JCI40483

108. Bala S, Marcos M, Kodys K, Csak T, Catalano D, Mandrekar P, et al. Up-regulation of microRNA-155 in macrophages contributes to increased tumor necrosis factor α (TNFα) production via increased mRNA half-life in alcoholic liver disease. J Biol Chem. (2011) 286:1436–44. doi: 10.1074/jbc.M110.145870

109. Klibi J, Niki T, Riedel A, Pioche-Durieu C, Souquere S, Rubinstein E, et al. Exosomes and immune tolerance. Rev Immunol. (2004) 22:531–62. doi: 10.1146/annurev.immunol.21.120601.141122

110. Hua J, Inomata T, Chen Y, Foulsham W, Stevenson W, Shiang T, et al. Pathological conversion of regulatory T cells is associated with loss of allotolerance. Sci Rep. (2018) 8:7059. doi: 10.1038/s41598-018-25384-x

111. Parisi L, Bassani B, Tremolati M, Gini E, Farronato G, Bruno A. Natural killer cells in the orchestration of chronic inflammatory diseases. J Immunol Res. (2017) 2017:4218254. doi: 10.1155/2017/4218254

112. Zitti B, Bryceon YT. Natural killer cells in inflammation and autoimmunity. Cytokine Growth Factor Rev. (2018) 42:37–46. doi: 10.1016/j.cytogfr.2018.03.016

113. Szczepanski MJ, Szajnik M, Welsh A, Whiteside TL, Boyiadzis M. Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-beta1. Haematologica. (2011) 96:1302–9. doi: 10.3324/haematol.2010.039743

114. Liu C, Yu S, Zinn K, Wang J, Zhang L, Jia Y, et al. Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function. J Immunol. (2006) 176:1375–85. doi: 10.4049/jimmunol.176.3.1375

115. Clayton A, Tabi Z. Exosomes and the MICA/NKG2D system in cancer. Blood Cells Mol Dis. (2005) 34:206–13. doi: 10.1016/j.bcmd.2005.03.003

116. Grindebeck H, Stenstad H, Quinding-Jarbrink M, Waldenstrom J, Adlerberth I, Wold AE, et al. Dynamic development of homing receptor expression and memory cell differentiation of infant CD4+CD25high regulatory T cells. J Immunol. (2009) 183:4360–70. doi: 10.4049/jimmunol.0901091

117. Burzyn D, Kuswanto W, Kolodin D, Shadrach JL, Cerletti M, Akbar AN, et al. Modulation of monocyte/macrophage function by immunosuppressive exosomes in leukemia/lymphoma T and B cells. PLoS ONE. (2011) 6:e16899. doi: 10.1371/journal.pone.0016899

118. Zhao DM, Thornton AM, DiPaolo RJ, Shevach EM. Activated CD4+ regulatory T cells selectively kill B lymphocytes. Blood. (2006) 107:3925–32. doi: 10.1182/blood-2006-02-142596

119. Kreyer-Bibens C, Pioche-Durieu C, Vilmann C, Souquere S, Nishi N, Hirashima M, et al. Exosomes released by EBV-infected nasopharyngeal carcinoma cells convey the viral latent membrane protein 1 and the immunomodulatory protein galectin 9. BMC Cancer. (2006) 6:283. doi: 10.1186/1471-2407-6-283

120. Othman et al. Cancer-Derived Exosomes and Inflammation

121. Total September 2019 | Volume 10 | Article 2103

122. Frontiers in Immunology | www.frontiersin.org

123. Box 1: Humoral immune escape

124. Wang Y, Ma Y, Fang Y, Wu S, Liu L, Fu D, et al. Regulatory T cell: a protection for tumour cells. J Cell Mol Med. (2012) 16:425–36. doi: 10.1111/j.1476-4687.2011.01347.x
135. Muller L, Simms P, Hong CS, Nishimura MI, Jackson K, Watkins SC, et al. Human tumor-derived exosomes (TEX) regulate Treg functions via cell surface signaling rather than uptake mechanisms. Oncoimmunology. (2017) 6:e1261243. doi: 10.1080/2162402X.2016.1261243

136. Sajnik M, Czyżowska M, Szczepanski MJ, Mandapathil M, Whiteside TL. Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg). PLoS ONE. (2010) 5:e11469. doi: 10.1371/journal.pone.0011469

137. Huang B, Zhao J, Li H, He KL, Chen Y, Chen SH, et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res. (2005) 65:5009–14. doi: 10.1158/0008-5472.CAN-05-0784

138. Kelly MG, Alvero AB, Chen R, Silasi DA, Abrahams VM, Chan S, et al. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res. (2006) 66:3859–68. doi: 10.1158/0008-5472.CAN-05-3948

139. Li D, Jia H, Zhang H, Lv M, Liu J, Zhang Y, et al. TLR4 signaling induces the release of microparticles by tumor cells that regulate inflammatory cytokine IL-6 of macrophages via microRNA let-7b. Oncoimmunology. (2012) 1:687–93. doi: 10.4161/oni.19854

140. Chen X, Ying X, Wang X, Wu X, Zhu Q, Wang X. Exosomes derived from hypoxic epithelial ovarian cancer deliver microRNA-940 to induce macrophage M2 polarization. Oncol Rep. (2017) 38:522–8. doi: 10.3892/or.2017.5697

141. Ying X, Wu Q, Wu X, Zhu Q, Wang X, Jiang L, et al. Epithelial ovarian cancer-secreted exosomal miR-222–3p induces polarization of tumor-associated macrophages. Oncotarget. (2016) 7:43076–87. doi: 10.18632/oncotarget.9246

142. Yoshimura A, Naka T, Kubo M. SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol. (2007) 7:454–65. doi: 10.1038/nri2093

143. Arnold CE, Whyte CS, Gordon P, Barker RN, Rees AJ, Wilson HM. A critical role for suppressor of cytokine signalling 3 in promoting M1 macrophage activation and function in vitro and in vivo. Immunology. (2014) 141:96–110. doi: 10.1111/imm.12173

144. Liu Y, Stewart KN, Bishop E, Marek CJ, Kluth DC, Rees AI, et al. Unique expression of suppressor of cytokine signalling 3 is essential for classical macrophage activation in rodents in vitro and in vivo. J Immunol. (2008) 180:6270–8. doi: 10.4049/jimmunol.180.9.6270

145. Soki FN, Koh AJ, Jones JD, Kim YW, Dai J, Keller ET, et al. Polarization of prostate cancer-associated macrophages is induced by milk fat globule-EGF factor 8 (MFG-E8)-mediated efferocytosis. J Biol Chem. (2014) 289:24560–72. doi: 10.1074/jbc.M114.571620

146. Gabrusiewicz K, Li X, Wei J, Hashimoto Y, Marisetti AL, Ott M, et al. Glioblastoma stem cell-derived exosomes induce M2 macrophages and PD-L1 expression on human monocytes. Oncoimmunology. (2018) 7:e142909. doi: 10.1080/2162402X.2017.1412909

147. Cooks T, Pateras IS, Jenkins LM, Patel KM, Robles AI, Morris I, et al. Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246. Nat Commun. (2018) 9:771. doi: 10.1038/s41467-018-03224-w

148. Yang M, Chen J, Su F, Yu B, Su F, Lin L, et al. Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells. Mol Cancer. (2011) 10:117. doi: 10.1186/1476-4598-10-117

149. Bell BM, Kirk ID, Hildbrunner S, Gabrielson S, Bulsema JJ. Designer exosomes as next-generation cancer immunotherapy. Nanomedicine. (2016) 12:163–9. doi: 10.1016/j.nano.2015.09.011

150. Morishita M, Takahashi Y, Matsumoto A, Nishikawa M, Takakura Y. Exosome-based tumor antigens-adjuvant co-delivery utilizing genetically engineered tumor cell-derived exosomes with immunostimulatory CpG DNA. Biomaterials. (2016) 111:55–65. doi: 10.1016/j.biomaterials.2016.09.031

151. Mahmoodzadeh Hosseini H, Imani Fooladi AA, Soleimanirad J, Nourani MR, Davaran S, Mahdavi M. Staphylococcal enterotoxin B anchored exosome induces apoptosis in negative estrogen receptor breast cancer cells. Tumour Biol. (2014) 35:5699–707. doi: 10.1007/s13277-014-1489-1

152. Cai X, Yin Y, Li N, Zhu D, Zhang J, Zhang CY, et al. Re-polarization of tumor-associated macrophages to pro-inflammatory M1 macrophages by microRNA-155. J Mol Cell Biol. (2012) 4:341–3. doi: 10.1093/jmcb/mjr044

153. Syn NL, Wang L, Chow EK, Lim CT, Goh BC. Exosomes in cancer nanomedicine and immunotherapy: prospects and challenges. Trends Biotechnol. (2017) 35:665–76. doi: 10.1016/j.tibtech.2017.03.004

154. Wozniak MB, Muller DC, Mukeria A, Zaridze D, Brennan P. Circulating microRNAs as non-invasive biomarkers for early detection of non-small-cell lung cancer. PLoS ONE. (2015) 10:e0125026. doi: 10.1371/journal.pone.0125026

155. Viaud S, Terme M, Flament C, Taieb J, Andre F, Novault S, et al. Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NK killer cells and IL-15Rs. PLoS ONE. (2009) 4:e4942. doi: 10.1371/journal.pone.0004942

156. Escudier B, Dorval T, Chaput N, Andre F, Nobault S, et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of the first phase I clinical trial. J Transl Med. (2005) 3:10. doi: 10.1186/1479-5876-3-10

157. Morse MA, Garst J, Osaka T, Khan S, Hobelka A, Clay TM, et al. A phase I study of desoxosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med. (2005) 3:9. doi: 10.1186/1479-5876-3-9

158. Besse B, Charrier M, Lapierre V, Dansin E, Lantz O, Planchard D, et al. Dendritic cell-derived exosomes as maintenance immunotherapy after first-line chemotherapy in NSCLC. Oncoimmunology. (2016) 5:e1071008. doi: 10.1080/2162402X.2015.1071008

159. Tran TH, Mattheolabakis G, Aldawarsi H, Amiji M. Exosomes as nanocarriers for immunotherapy of cancer and inflammatory diseases. Clin Immunol. (2015) 160:46–58. doi: 10.1016/j.clim.2015.03.021

160. Batista IA, Melo SA. Exosomes and the Future of Immunotherapy in Pancreatic Cancer. Int J Mol Sci. (2019) 20:E857. doi: 10.3390/ijms20030567

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.